Contributed by NAMPA / AFP.
Press Release from Business Wire : Chugai Pharmaceutical Co., Ltd.
ATTENTION - Usable ///
TOKYO, April 17, 2018 (BSW) - Chugai
Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S.
Food and Drug Administration (FDA) has granted Breakthrough Therapy
Designation for its anti-coagulation factor IXa/X humanized bispecific
monoclonal antibody / coagulation factor VIII substitute, "HEMLIBRAŽ"
[US generic name: emicizumab-kxwh] for people with hemophilia A ...